Clinical Report: Combination of Anti-PD-1 Monoclonal Antibody and Chemotherapy in Treating Porocarcinoma
Overview
This case study presents a 78-year-old female with porocarcinoma who received a combination of penpulimab and nab-paclitaxel, achieving a partial response initially. However, the patient ultimately experienced disease progression, highlighting the challenges in treating this rare malignancy.
Background
Porocarcinoma (PC) is an extremely rare skin cancer with a poor prognosis due to its high risk of metastasis. Current treatment options are limited, and no standard protocols exist, making it crucial to explore novel therapeutic strategies. Recent studies suggest that immune checkpoint inhibitors may offer promising efficacy in managing this aggressive neoplasm.
Data Highlights
No numerical data available in the article.
Key Findings
The patient achieved a partial response after 2 cycles of combination therapy.
Stable disease was observed after 4 cycles, followed by progressive disease after 5 cycles.
Next-generation sequencing indicated a high tumor mutational burden of 13.4 mutations/Mb.
Combination therapy with anti-PD-1 and chemotherapy may be a viable option for refractory porocarcinoma.
Acquired resistance was noted during the treatment course, emphasizing the need for ongoing research.
Clinical Implications
The case underscores the potential of combining immune checkpoint inhibitors with chemotherapy in treating porocarcinoma, although resistance can develop. Clinicians should consider this combination as a therapeutic option while remaining vigilant for signs of disease progression.
Conclusion
This case report highlights the therapeutic challenges and potential of combination therapy in porocarcinoma, warranting further investigation into effective treatment strategies for this rare malignancy.
